Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1186/s13075-016-1049-3
Published Online: 2016-06-23
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Genovese, Mark C.
van Vollenhoven, Ronald F.
Wilkinson, Bethanie
Wang, Lisy
Zwillich, Samuel H.
Gruben, David
Biswas, Pinaki
Riese, Richard
Takiya, Liza
Jones, Thomas V.
Funding for this research was provided by:
Pfizer Inc
